High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis-Reference-Cited by-同舟云学术

High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis

Published:2018-08 Issue:2 Volume:69 Page:293-300
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Puoti Massimo,Foster Graham R.,Wang Stanley,Mutimer David,Gane Edward,Moreno Christophe,Chang Ting Tsung,Lee Samuel S.,Marinho Rui,Dufour Jean-Francois,Pol Stanislas,Hezode Christophe,Gordon Stuart C.,Strasser Simone I.,Thuluvath Paul J.,Zhang Zhenzhen,Lovell Sandra,Pilot-Matias Tami,Mensa Federico J.

Funder

AbbVie

Publisher

Elsevier BV

Subject

Hepatology

Reference32 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study;Lancet Gastroenterol Hepatol,2017

2. http://polarisobservatory.org/polaris/graphs.htm (accessed 10 July 2017).

3. AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus, 2017.

4. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018;69:461–511.

5. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2;Hatzakis;J Viral Hepat,2015

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn?;Journal of Medicinal Chemistry;2024-01-05

2. Mendelian Randomization Analysis Reveals Hepatitis C Infection is Causally Associated with Extrahepatic Cancer;2024

3. Development and optimisation of a reception testing protocol designed to eliminate HCV in the UK prison population;JHEP Reports;2024-01

4. The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort;HEPATOL FORUM;2023

5. A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada;Scientific Reports;2023-08-18